Atorvastatin Rapidly Reduces Hepatitis B Viral Load in Combination with Tenofovir: A Prospective Clinical Trial
Objective and Aim. Atorvastatin inhibits cholesterol synthesis which is critically important in the formation of the viral envelope and secretion. The efficacy and safety of giving atorvastatin (40 mg/day) as an adjunct to tenofovir in the treatment of hepatitis B (HBV) were assessed. Method. In thi...
Saved in:
| Main Authors: | M. Gharehbeglou, S. Yazdani, K. White, M. R. Haeri, N. Masoumzadeh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
| Online Access: | http://dx.doi.org/10.1155/2022/3443813 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Renal Concerns in the Treatment of Chronic Hepatitis B with Tenofovir
by: Giuseppe Coppolino, et al.
Published: (2017-03-01) -
Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate
by: Shenglong Lin, et al.
Published: (2024-11-01) -
The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
by: Elise Chia-Hui Tan, et al.
Published: (2025-03-01) -
Acquired Fanconi Syndrome from Tenofovir Treatment in a Patient with Hepatitis B
by: Shirley X. Jiang, et al.
Published: (2023-01-01) -
Viral load in chronic hepatitis b: correlation with laboratory and morphological parameters
by: E. V. Esaulenko, et al.
Published: (2014-09-01)